The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Time to tumor progression (TTP)
Time from randomization to the first documentation of progressive disease based on the Myeloma response determination criteria developed by Bladé et al 1998
Up to 23 months
Robert Knight, MD
United States: Food and Drug Administration